Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTemis: Bevacizumab with Neoadjuvant Chemotherapy in Early Breast Cancer
NCT01093235Phase 3Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Apr 2009
- Primary completion
- Apr 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in breast cancer (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Pathological Complete Response Rate. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01093235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01093235.